Person: AKBAŞ, FAHRİ
2 results
Search Results
Now showing 1 - 2 of 2
Publication Metadata only The Effects of Transcranial Focused Ultrasound Stimulation of Nucleus Accumbens on Neuronal Gene Expression and Brain Tissue in High Alcohol-Preferring Rats(2022-11-01) Deveci E.; Akbaş F.; Ergun A. Ş.; Kurtulmuş A.; Koçak A. B.; Boyraz R. K.; Tok O. E.; Aydın M. Ş.; Kılıç Ö.; Bozkurt A.; et al.; AKBAŞ, FAHRİ; KILIÇ, ÖZGE; EŞREFOĞLU, MUKADDES; KOÇYİĞİT, ABDÜRRAHİM; KIRPINAR, İSMETWe investigated the effect of low-intensity focused ultrasound (LIFU) on gene expression related to alcohol dependence and histological effects on brain tissue. We also aimed at determining the miRNA-mRNA relationship and their pathways in alcohol dependence-induced expression changes after focused ultrasound therapy. We designed a case-control study for 100 days of observation to investigate differences in gene expression in the short-term stimulation group (STS) and long-term stimulation group (LTS) compared with the control sham group (SG). The study was performed in our Experimental Research Laboratory. 24 male high alcohol-preferring rats 63 to 79 days old, weighing 270 to 300 g, were included in the experiment. LTS received 50-day LIFU and STS received 10-day LIFU and 40-day sham stimulation, while the SG received 50-day sham stimulation. In miRNA expression analysis, it was found that LIFU caused gene expression differences in NAc. Significant differences were found between the groups for gene expression. Compared to the SG, the expression of 454 genes in the NAc region was changed in the STS while the expression of 382 genes was changed in the LTS. In the LTS, the expression of 32 genes was changed in total compared to STS. Our data suggest that LIFU targeted on NAc may assist in the treatment of alcohol dependence, especially in the long term possibly through altering gene expression. Our immunohistochemical studies verified that LIFU does not cause any tissue damage. These findings may lead to new studies in investigating the efficacy of LIFU for the treatment of alcohol dependence and also for other psychiatric disorders.Publication Metadata only Genetik jeneralize epilepside miRNA'ların genetik biyobelirteçler olarak değerlendirilmesi(2023-12-31) Bozkurt S.; Korkmaz N. D.; Bilge B. N.; Yabacı Tak A.; Bayrakoğlu A.; Uslu İlgen F.; Yücesan E.; Akbaş F.; KORKMAZ, NUR DAMLA; YABACI TAK, AYŞEGÜL; AKBAŞ, FAHRİEvaluation of miRNAs as genetic biomarkers in genetic generalized epilepsySimay Bozkurt1, Nur Damla Korkmaz2, Bilge Nur Bilge3, Aysegul Yabaci Tak4, Alisan Bayrakoglu5, Ferda Uslu Ilgen5, Emrah Yucesan6, Fahri Akbas1,21Bezmialem Vakif University, Institute of Health Sciences, Department of Biotechnology, Istanbul, Türkiye.2Bezmialem Vakif University, Faculty of Medicine, Department of Medical Biology, Istanbul, Türkiye.3Istanbul University-Cerrahpasa, Institute of Neurological Sciences, Department of Neuroscience, Istanbul, Türkiye.4Bezmialem Vakif University, Faculty of Medicine, Department of Basic Medical Sciences, Department of Biostatistics and Medical Informatics, Istanbul, Türkiye.5Bezmialem Vakif University, Faculty of Medicine, Department of Neurology, Istanbul, Türkiye.6Istanbul University-Cerrahpasa, Institute of Neurological Sciences, Department of Neurogenetics, Istanbul, Türkiye.Objective: Genetic generalized epilepsy (GGE) is a subtype of epilepsy that involves the entire brain and has a genetic etiology. GGE accounts for 15-20% of all epilepsies. There is no specific genetic biomarker widely used that contributes to the diagnostic process of this disease. In the last decade, there has been a radical increase in the number of studies on the use of small non-coding RNAs found in the human genome as genetic biomarkers for various neurological diseases. MicroRNAs (miRNAs), the best-known small non-coding RNAs, play a critical role in regulating neuronal biological processes through the modulation of gene expression. Therefore, miRNAs have assumed an important role in biomarker research due to their stability in clinical samples. In our study, we examined the expression levels of miR-106b, miR-130a-3p, and miR-194-5p in GGE patients with the aim of evaluating their performance as diagnostic biomarkers.Methods: 21 patients with isolated GGE and 18 healthy controls were recruited in this study and total RNA was extracted from blood samples of participants. cDNA synthesis was performed from the obtained RNAs. The expression levels of miR-106b, miR-130a-3p and miR-194-5p were analyzed via qRT-PCR, and receiver operating characteristic (ROC) curves were generated and area under the curve (AUC) was calculated to evaluate the diagnostic values.Results: The expression level of miR-130a-3p has shown statistically significant increase in patients compared to controls (p<0.05). The AUC value determined in the ROC analysis is 0.725. However, the expression levels of miR-106b and miR-194-5p are not detected statistically significant. Their AUC values in the ROC analysis are 0.648 and 0.571, respectively.Conclusion: The varying expression levels of miRNAs that we used in our study may be associated with the etiopathogenesis of GGE. Our findings suggest using miR-130a-3p as potential biomarker in the diagnosis and prognosis of GGE.Keywords: Genetic biomarker, genetic generalized epilepsy, microRNA, ROC curve.Acknowledgement: This study was supported by Bezmialem Foundation University, Scientific Research Projects Unit (Project no: 20230205).29Objective: Genetic generalized epilepsy (GGE) is a subtype of epilepsy that involves the entire brain and has a genetic etiology. GGE accounts for 15-20% of all epilepsies. There is no specific genetic biomarker widely used that contributes to the diagnostic process of this disease. In the last decade, there has been a radical increase in the number of studies on the use of small non-coding RNAs found in the human genome as genetic biomarkers for various neurological diseases. MicroRNAs (miRNAs), the best-known small non-coding RNAs, play a critical role in regulating neuronal biological processes through the modulation of gene expression. Therefore, miRNAs have assumed an important role in biomarker research due to their stability in clinical samples. In our study, we examined the expression levels of miR-106b, miR-130a-3p, and miR-194-5p in GGE patients with the aim of evaluating their performance as diagnostic biomarkers.Methods: 21 patients with isolated GGE and 18 healthy controls were recruited in this study and total RNA was extracted from blood samples of participants. cDNA synthesis was performed from the obtained RNAs. The expression levels of miR-106b, miR-130a-3p and miR-194-5p were analyzed via qRT-PCR, and receiver operating characteristic (ROC) curves were generated and area under the curve (AUC) was calculated to evaluate the diagnostic values.Results: The expression level of miR-130a-3p has shown statistically significant increase in patients compared to controls (p<0.05). The AUC value determined in the ROC analysis is 0.725. However, the expression levels of miR-106b and miR-194-5p are not detected statistically significant. Their AUC values in the ROC analysis are 0.648 and 0.571, respectively.Conclusion: The varying expression levels of miRNAs that we used in our study may be associated with the etiopathogenesis of GGE. Our findings suggest using miR-130a-3p as potential biomarker in the diagnosis and prognosis of GGE.Keywords: Genetic biomarker, genetic generalized epilepsy, microRNA, ROC curve.Acknowledgement: This study was supported by Bezmialem Foundation University, Scientific Research Projects Unit (Project no: 20230205).29